Sino Biological/Her2/ERBB2 Protein, Human, Recombinant (ECD, His Tag)/1/10004-H08H
商品编号：
10004-H08H
品牌：
sinobiological
市场价：
¥0.00
美元价：
0.00
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
Her2/ERBB2 Protein, Human, Recombinant (ECD, His Tag): Product Information
Purity
> 90 % as determined by SDS-PAGE
Endotoxin
< 1.0="" eu="" per="" μg="" of="" the="" protein="" as="" determined="" by="" the="" lal="">
Activity
1. Measured by its binding ability in a functional ELISA.Immobilized human Erbb2 at 2.5 μg/ml (100 μl/well) can bind Herceptin with a linear range of 1.28-32 ng/ml.2. Measured by its ability to block anti-ErbB2 mediated inhibition of BT474 human breast ductal carcinoma cell proliferation. The ED50 for this effect is 0.3-1.8 μg/mL in the presence of 0.6 µg/mL Anti-ErbB2/Her2 Monoclonal Antibody.3. Using the Octet RED System, the affinity constant (Kd) of Her2 / ERBB2 Protein, Human, Recombinant (His Tag) (Cat: 10004-H08H) bound to Pertuzumab was 0.1 nM.
Protein Construction
A DNA sequence encoding the extracellular domain (Met 1-Thr 652) of human ErbB2 (NP_004439.2) was fused with the polyhistidine tag at the C-terminus.
Accession#
NP_004439.2
Expressed Host
HEK293 Cells
Species
Human
Predicted N Terminal
Thr 23
Molecule Mass
The recombinant human ErbB2 comprises 641 amino acids and has a calculated molecular mass of 71 kDa. As a result of glycosylation, rh ErbB2 migrates as an approximately 100-110 kDa protein in SDS-PAGE under reducing conditions.
Formulation
Lyophilized from sterile PBS, pH 7.4Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
Please refer to the specific buffer information in the hard copy of CoA.
Shipping
In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
Stability & Storage
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Reconstitution
A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.
Her2/ERBB2 Protein, Human, Recombinant (ECD, His Tag): Images
Measured by its ability to block anti-ErbB2 mediated inhibition of BT474 human breast ductal carcinoma cell proliferation. The ED50 for this effect is 0.3-1.8 μg/mL in the presence of 0.6 µg/mL Anti-ErbB2/Her2 Monoclonal Antibody.
Measured by its binding ability in a functional ELISA. Immobilized human Erbb2 at 2.5 μg/ml (100 μl/well) can bind Herceptin with a linear ranger of 1.28-32 ng/ml.
Using the Octet RED System, the affinity constant (Kd) of Her2 / ERBB2 Protein, Human, Recombinant (His Tag) (Cat: 10004-H08H) bound to Pertuzumab was 0.1 nM.
Her2/ERBB2 Protein, Human, Recombinant (ECD, His Tag): Synonyms
CD340 Protein, Human; ENV Protein, Human; ENVW Protein, Human; ERVWE1 Protein, Human; HER-2 Protein, Human; HER-2/neu Protein, Human; HER2 Protein, Human; HERV-7q Protein, Human; HERV-W-ENV Protein, Human; HERV7Q Protein, Human; HERVW Protein, Human; HERVWENV Protein, Human; MLN 19 Protein, Human; MLN19 Protein, Human; NEU Protein, Human; NGL Protein, Human; TKR1 Protein, Human
Her2/ERBB2 Background Information
Human epidermal growth factor receptor 2 (HER2), also known as ErbB2, NEU, and CD340, is a type I membrane glycoprotein and belongs to the epidermal growth factor (EGF) receptor family. HER2 protein cannot bind growth factors due to the lacking of ligand binding domain of its own and autoinhibited constitutively. However, HER2 forms a heterodimer with other ligand-bound EGF receptor family members, therefore stabilizes ligand binding and enhances kinase-mediated activation of downstream molecules. HER2 plays a key role in development, cell proliferation and differentiation. HER2 gene has been reported to associate with malignancy and a poor prognosis in numerous carcinomas, including breast, prostate, ovarian, lung cancers and so on.
- Cancer Immunotherapy
- Immune Checkpoint
- Immunotherapy
- Targeted Therapy
Full Name
erb-b2 receptor tyrosine kinase 2
Research Areas
- Cancer Drug Targets
- Receptor Tyrosine Kinases (RTKs)
References
- Krawczyk N, et al. (2009) HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res. 29(10): 4019-24.
Human Her2/ERBB2 Proteins
- Her2/ERBB2 Protein, Human, Recombinant (ECD, domain I, His Tag)10004-H08H1
- Her2/ERBB2 Protein, Human, Recombinant (ECD, domain IV, His Tag)10004-H08H4
- Her2/ERBB2 Protein, Human, Recombinant (His & AVI Tag), Biotinylated10004-H27H-B
- Her2/ERBB2 Protein, Human, Recombinant (aa 676-1255, His & GST Tag)10004-H20B1
- Her2/ERBB2 Protein, Human, Recombinant (ECD, hFc Tag)10004-H02H
- Her2/ERBB2 Protein, Human, Recombinant (ECD, His Tag), Biotinylated10004-H08H-B
- Her2/ERBB2 Protein, Human, Recombinant (ECD), Biotinylated10004-HCCH-B
- Her2/ERBB2 Protein, Human, Recombinant (hFc Tag), Biotinylated10004-H02H-B
- Her2/ERBB2 Protein, Human, Recombinant (ECD, His Tag), Biotinylated10004-H08H1-B
- Her2/ERBB2 Protein, Human, Recombinant (ECD, His Tag), Biotinylated10004-H08H4-B
- Her2/ERBB2 Protein, Human, Recombinant (ECD)10004-HCCH
Mouse Her2/ERBB2 Proteins
- Her2/ERBB2 Protein, Mouse, Recombinant (His Tag)50714-M08H
- Her2/ERBB2 Protein, Mouse, Recombinant (hFc Tag)50714-M02H
Rat Her2/ERBB2 Proteins
- Her2/ERBB2 Protein, Rat, Recombinant (hFc Tag)80079-R02H
- Her2/ERBB2 Protein, Rat, Recombinant (His Tag)80079-R08H
- Her2/ERBB2 Protein, Rat, Recombinant80079-RCCH
Cynomolgus Her2/ERBB2 Proteins
- Her2/ERBB2 Protein, Cynomolgus, Recombinant (His Tag)90295-C08H
- Her2/ERBB2 Protein, Cynomolgus, Recombinant (ECD, hFc Tag)90295-C02H
Rhesus Her2/ERBB2 Proteins
- Her2/ERBB2 Protein, Rhesus, Recombinant (hFc Tag)90020-K02H
- Her2/ERBB2 Protein, Rhesus, Recombinant (His Tag)90020-K08H
Canine Her2/ERBB2 Proteins
- Her2/ERBB2 Protein, Canine, Recombinant (His Tag)70024-D08H
- Expression of recombinant multi-coloured fluorescent antibodies in gor -/trxB- E. coli cytoplasmAuthorMarkiv, A;Beatson, R;Burchell, J;Durvasula, RV;Kang, AS;Year2011JournalBMC Biotechnol.ApplicationSPRPubMed ID: 22129156FoldedExpand
- Modified trastuzumab and cetuximab mediate efficient toxin delivery while retaining antibody-dependent cell-mediated cytotoxicity in target cellsAuthorGilabert-Oriol, R;Thakur, M;von Mallinckrodt, B;Hug, T;Wiesner, B;Eichhorst, J;Melzig, MF;Fuchs, H;Weng, A;Year2013JournalMol. Pharm.ApplicationSPRPubMed ID: 24050452FoldedExpand
- Development of an immunoassay for human epidermal growth factor receptor 2 (HER2)AuthorHenanger, KJ;Year2014JournalThesisFoldedExpand
- Engineering of Bispecific Affinity Proteins with High Affinity for ERBB2 and Adaptable Binding to AlbuminAuthorNilvebrant, J;Astrand, M;Georgieva-Kotseva, M;Björnmalm, M;Löfblom, J;Hober, S;Year2014JournalPLoS ONEApplicationremaining tracksPubMed ID: 25089830FoldedExpand
- Exploring the effects of linker composition on site-specifically modified antibody-drug conjugatesAuthorAE Albers, AW Garofalo, PM Drake, R Kudirka…Year2014JournalEuropean Journal of Medicinal ChemistryApplicationELISAPubMed ID: 25176286FoldedExpand
- Surface plasmon resonance immunosensor for ErbB2 breast cancer biomarker determination in human serum and raw cancer cell lysatesAuthorEletxigerra, U;Martinez-Perdiguero, J;Barderas, R;Pingarrón, JM;Campuzano, S;Merino, S;Year2016JournalAnal. Chim. ActaPubMed ID: 26755150FoldedExpand
- Molecular and hydrodynamic properties of human epidermal growth factor receptor HER2 extracellular domain and its homodimer: Experiments and multi-scale simulationsAuthorVega, JF;Ramos, J;Cruz, V;Vicente-Alique, E;Sánchez-Sánchez, E;Sánchez-Fernández, A;Wang, Y;Hu, P;Cortés, J;Martínez-Salazar, J;Year2017JournalBiochim. Biophys. ActaPubMed ID: 28642126FoldedExpand
- Ultra-low fouling methylimidazolium modified surfaces for the detection of HER2 in breast cancer cell lysatesAuthorAubé, A;Campbell, S;Schmitzer, AR;Claing, A;Masson, JF;Year2017JournalAnalystPubMed ID: 28560368FoldedExpand
- Single-step Enzymatic Glycoengineering for the Construction of Antibody-cell ConjugatesAuthorLi, J;Chen, M;Liu, Z;Zhang, L;Felding, B;Lauvau, G;Abadier, M;Ley, K;Wu, P;Year2018JournalbioRxivApplicationbindingFoldedExpand
- Site-Specific Photoconjugation of Beta-Lactamase Fragments to Monoclonal Antibodies Enables Sensitive Analyte Detection via Split-Enzyme ComplementationAuthorYu, F;Alesand, V;Nygren, PÅ;Year2018JournalBiotechnol JApplicationbindingPubMed ID: 29485240FoldedExpand
- Structural and functional characterization of MBS301, an afucosylated bispecific anti-HER2 antibodyAuthorHuang, S;Li, F;Liu, H;Ye, P;Fan, X;Yuan, X;Wu, Z;Chen, J;Jin, C;Shen, B;Feng, J;Zhang, B;Year2018JournalMAbsApplicationSPRPubMed ID: 30081724FoldedExpand
- High-resolution glycosylation site-engineering method identifies MICA epitope critical for shedding inhibition activity of anti-MICA antibodiesAuthorLombana, TN;Matsumoto, ML;Bevers Iii, J;Berkley, AM;Toy, E;Cook, R;Gan, Y;Du, C;Liu, P;Schnier, P;Sandoval, W;Ye, Z;Schartner, JM;Kim, J;Spiess, C;Year2018JournalMAbsApplicationcontrolPubMed ID: 30307368FoldedExpand
- Hydrodynamic and electrophoretic properties of Trastuzumab/HER2 complexes. Experiments and modeling.AuthorRamos, J;Vega, J;Cruz, V;Sanchez-Sanchez, E;Cortes, J;Martinez-Salazar, J;Year2018JournalbioRxivApplicationbindingFoldedExpand
- Constructive approach for synthesis of a functional IgG using a reconstituted cell-free protein synthesis systemAuthorMurakami, S;Matsumoto, R;Kanamori, T;Year2019JournalSci RepApplicationELISA and OctetPubMed ID: 30679500FoldedExpand
- Hydrodynamic and Electrophoretic Properties of Trastuzumab/HER2 Extracellular Domain Complexes as Revealed by Experimental Techniques and Computational SimulationsAuthorRamos, J;Vega, JF;Cruz, V;Sanchez-Sanchez, E;Cortes, J;Martinez-Salazar, J;Year2019JournalInt J Mol SciApplicationbindingPubMed ID: 30832287FoldedExpand
- VHH characterization.Recombinant VHHs: Production, characterization and affinityAuthorChabrol, E;Stojko, J;Nicolas, A;Botzanowski, T;Fould, B;Antoine, M;Cianférani, S;Ferry, G;Boutin, J;Year2019JournalAnalytical BiochemistryApplicationSPRFoldedExpand
- Elucidating the Binding Mechanism of a Novel Silica-Binding PeptideAuthorBansal, R;Elgundi, Z;Care, A;Goodchild, SC;Lord, MS;Year2020JournalBiomoleculesApplicationSPRFoldedExpand
- Labeling-free detection of ECD-HER2 protein using aptamer-based nano-plasmonic sensorAuthorKim, J;Suh, JS;Yang, J;Year2020JournalNanotechnologyApplicationmedical nanoparticle processPubMed ID: 31914433FoldedExpand
- The Effect of Oligomerization on A Solid-Binding Peptide Binding to Silica-Based MaterialsAuthorBansal, R;Elgundi, Z;Goodchild, SC;Care, A;Lord, MS;Rodger, A;Sunna, A;Year2020JournalNanomaterials (Basel)ApplicationbindingPubMed ID: 32486317FoldedExpand
- Biophysical and biochemical characterization of a VHH-based IgG-like bi- and trispecific antibody platformAuthorPekar, L;Busch, M;Valldorf, B;Hinz, S;Toleikis, L;Krah, S;Zielonka, S;Year2020JournalmAbsFoldedExpand
If you couldn"t find the specific citation, you can:
- Find All Citations
- Submit a CitationGet a Publication Reward
- Leave Us a Message
E.coli protein expression service
Mammalian transient protein expression service
Baculovirus-insect expression service
Stable cell line development service (CHO / HEK293)
品牌介绍
北京义翘神州科技股份有限公司（Sino Biological Inc.）是一家从事生物试剂研发、生产、销售并提供技术服务的生物科技公司，主要业务包括重组蛋白、抗体、基因和培养基等产品，以及重组蛋白、抗体的开发和生物分析检测等服务。义翘神州为全球的药品研发企业和生命科学研究机构提供高质量的生物试剂产品和高水平的技术服务。公司目前生产和销售的现货产品种类超过 4.6 万种，其中重组蛋白约 6,000 种，包括超过 3,800 种人源细胞表达重组蛋白产品，能够全面满足客户对于最接近人体天然蛋白结构和性质的重组蛋白需求；公司还能提供约 12,000 种抗体，其中单克隆抗体数量约 4,600 种，能够覆盖生命科学研究的多个领域，为分子生物学、细胞生物学、免疫学、发育生物学、干细胞研究等基础科研方向和创新药物研发提供「一站式」生物试剂产品和技术服务。义翘神州的客户涵盖大学、科研院所、医药研发企业等国内外各类生物研发单位。目前公司已经在美国、欧洲建立了子公司，已成为生物试剂行业国内领先的科技公司之一。
联络我们
